Japanese Red Cross Society Himeji Hospital
Himeji, Hyogo, Japan
General hospital in Himeji
1 Chome-12-1 Shimoteno, Himeji, Hyogo 670-8540
About Japanese Red Cross Society Himeji Hospital
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Amgen
2
Eli Lilly and Company
2
Hoffmann-La Roche
2
Incyte Corporation
2
Bioverativ, a Sanofi company
1
Celgene
1
Daiichi Sankyo Co., Ltd.
1
Gynecologic Oncology Trial & Investigation Consortium
1
Institut de Recherches Internationales Servier
1
Japanese Gynecologic Oncology Group
1
Kyowa Kirin Co., Ltd.
1
Clinical Trials at Japanese Red Cross Society Himeji Hospital
During the past decade, Japanese Red Cross Society Himeji Hospital conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 4 clinical trials were completed, i.e. on
average, 30.8% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
2010-05-01
2021-02-28
Completed
655
A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease
2014-12-30
2020-07-17
Completed
207
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
2017-06-26
2024-06-30
Active, not recruiting
146
A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion
2018-03-17
2021-12-03
Completed
42
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)
2018-08-02
2021-10-20
Completed
778
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
2019-09-09
2022-04-01
Terminated
1,156
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
2019-05-08
2023-03-31
Completed
454
An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion
2019-05-20
2023-04-30
Active, not recruiting
21
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Japanese Red Cross Society Himeji Hospital" #1 sponsor was "Amgen" with 2 trials, followed by "Eli Lilly and Company" with 2 trials
sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "Incyte Corporation" with 2 trials sponsored and "Bioverativ, a Sanofi company"
with 2 trials sponsored. Other sponsors include 2 different institutions and
companies that sponsored additional 12 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Japanese Red Cross Society Himeji Hospital"
#1 collaborator was "Incyte Corporation" with 2 trials as a collaborator, "Japan Blood Products Organization" with 1 trials as a collaborator, "Japanese Gynecologic Oncology Group" with 1 trials as a collaborator and "Korean Gynecologic Oncology Group" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were
collaborators in the rest 4 trials.
Clinical Trials Conditions at Japanese Red Cross Society Himeji Hospital
According to Clinical.Site data, the most researched conditions in "Japanese Red Cross Society Himeji Hospital" are
"Epithelial Ovarian Cancer" (2 trials), "Myelofibrosis" (2 trials), "Post Essential Thrombocythemia Myelofibrosis" (2 trials), "Post Polycythemia Vera Myelofibrosis" (2 trials) and "Primary Myelofibrosis" (2 trials). Many other conditions were trialed in "Japanese Red Cross Society Himeji Hospital" in a lesser frequency.
Clinical Trials Intervention Types at Japanese Red Cross Society Himeji Hospital
Most popular intervention types in "Japanese Red Cross Society Himeji Hospital" are "Drug" (16 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (5 trials), "placebo" (3 trials), "Atezolizumab" (2 trials), "Baricitinib" (2 trials) and "parsaclisib" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Japanese Red Cross Society Himeji Hospital
The vast majority of trials in "Japanese Red Cross Society Himeji Hospital" are
13 trials for "All" genders and 3 trials for "Female" genders.
Clinical Trials Status at Japanese Red Cross Society Himeji Hospital
Currently, there are NaN active trials in "Japanese Red Cross Society Himeji Hospital".
undefined are not yet recruiting,
5 are recruiting,
4 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 6 completed trials in Japanese Red Cross Society Himeji Hospital,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Japanese Red Cross Society Himeji Hospital, 0 "Phase 1"
clinical trials were conducted, 2 "Phase 2" clinical
trials and 15 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".